ResultsIQ › Latest results › Novartis India Limited
Novartis India Limited Q2 FY27 results press release summary
NSE: NOVARTIND · BSE: 500672
Results press release of 3 Nov 2026, summarised by AI from the filing.
Evonile Pharma's first results after ChrysCapital's 70.68% controlling stake: Q2 FY27 revenue ₹56.1 cr and operating EBITDA -₹31.8 cr.
Key takeaways
- Q2 revenue Revenue from operations was ₹56.1 cr in Q2 FY27.
- Operating EBITDA Operating EBITDA was -₹31.8 cr, reflecting one-time transition costs and upfront investment in the organisational build-out.
- Change of control ChrysCapital acquired a controlling 70.68% stake in the Company during the quarter.
- New model The Company moved from a single-customer business model to its own distribution network, field force and operating systems.
- Portfolio The Company completed the Minipress XL acquisition and an ophthalmology in-licensing agreement, adding cardiology and ophthalmology.
Novartis India Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.